Clinical trials: Arrhythmogenic Right Ventricular Cardiomyopathy, open to volunteers
Cardiovascular Diseases, Hypertrophic Cardiomyopathy (HCM)
AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA
The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in…
- Conditions
- Cardiovascular Diseases, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Restrictive Cardiomyopathy
- Trial name
- Atlantis (NCT06748261)
- Testing
- CCTAI model
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Dilated Cardiomyopathies, Hypertrophic Cardiomyopathy
Sahlgrenska Cardiomyopathy Project
This is a joint project by Sahlgrenska University Hospital: Sahlgrenska, Östra and Mölndal. Our objective is to diagnose and map patients with well phenotyped cardiomyopathies (CMP) including in depth clinical and molecular…
- Conditions
- Dilated Cardiomyopathies, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
- Trial name
- NCT03527342
- Where
- Sweden
- Volunteers
- 3,000 people
- Sponsor
- Göteborg University
Cardiomyopathies, Heart Diseases
PKP2-ACM Natural History Study
The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.
- Conditions
- Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Genetic Diseases
- Trial name
- NCT06644742
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 36 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy, Cardiac Sarcoidosis, Hypertensive Heart Disease
- Trial name
- CHIEFTain (NCT06409585)
- Testing
- 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR, Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome
Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
Every week in the UK, 12 apparently healthy and fit individuals under the age of 35 die suddenly, a tragic event known as sudden cardiac death (SCD).
- Conditions
- Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Cardiac Channelopathy
- Trial name
- NCT04257994
- Testing
- obtaining a buccal smear sample
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- St. George's Hospital, London
Ventricular Arrythmia
China Structural Ventricular Arrhythmias Registry
This is an observational, prospective, multi-center registry ,aiming at building a risk stratification for malignant structural ventricular arrhythmias.
- Trial name
- NCT03821051
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- China National Center for Cardiovascular Diseases
Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype…
- Trial name
- TaRGET (NCT06174220)
- Testing
- Tideglusib
- Where
- 17 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Hamilton Health Sciences Corporation
Arrhythmogenic Right Ventricular Dysplasia
Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation.
- Trial name
- LI-ARVC (NCT05209776)
- Testing
- Peripheral immunological assessment on venous blood, Immunological assessment carried out on intracardiac material
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Toulouse
Arrhythmogenic Right Ventricular Cardiomyopathy
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2…
- Trial name
- RIDGE (NCT06311708)
- Where
- 21 sites in United States, France and 4 more
- Volunteers
- 200 people
- Sponsor
- Tenaya Therapeutics
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated
National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry
The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data.
- Conditions
- Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated, Cardiomyopathy Restrictive, Arrhythmogenic Right Ventricular Dysplasia
- Trial name
- RENOMICA-Hcor (NCT06546137)
- Testing
- whole genome sequencing
- Where
- 27 sites in Brazil
- Volunteers
- 1,211 people
- Sponsor
- Hospital do Coracao
Cardiomyopathies, Dilated Cardiomyopathy
Pediatric Cardiomyopathy Mutation Analysis
The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder.
- Conditions
- Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy
- Trial name
- NCT02432092
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Indiana University
Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET
FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disease associated with fibrofatty myocardial replacement, ventricular arrhythmias, and an increased risk of sudden cardiac death.
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy, FAPI PET, Cardiac Magnetic Resonance Imaging
- Trial name
- FAPI-ARVC (NCT07563660)
- Testing
- 68Ga-DOTA-SA-FAPI PET/CT
- Where
- Turkey (Türkiye)
- Volunteers
- 15 people
- Sponsor
- Istanbul University - Cerrahpasa
Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy
DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP).
- Conditions
- Non-ischemic Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy
- Trial name
- TORCH-Plus (NCT04265040)
- Where
- Germany
- Volunteers
- 2,040 people
- Sponsor
- University Hospital Heidelberg
Arrhythmogenic Cardiomyopathy (AC, ARVD/C)
Cardiac Rehabilitation in Patients With High-Genetic-Risk Arrhythmogenic Cardiomyopathy: The HGEN-CARE-AC Trial
The goal of this clinical trial is to evaluate a structured and personalized cardiac rehabilitation program for patients diagnosed with arrhythmogenic cardiomyopathy (ACM) who carry high-risk genetic mutations.
- Trial name
- HGEN-CARE-AC (NCT07708311)
- Testing
- Cardiac Rehabilitation Programme
- Volunteers
- 70 people
- Sponsor
- Juan Jiménez Jáimez
Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Ventricular Tachycardia (VT)
Treatment Registry of Arrhythmias, Complications and Electrocardiograms in Arrhythmogenic CardioMyopathies
TRACE-ACM is a multicenter, retrospective, observational study of patients with arrhythmogenic cardiomyopathy who received an implantable cardioverter-defibrillator (ICD) and had documented ventricular tachyarrhythmias.
- Conditions
- Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Ventricular Tachycardia (VT), Ventricular Fibrillation, ICD
- Trial name
- TRACE-ACM (NCT07688200)
- Volunteers
- 300 people
- Sponsor
- Policlinico Casilino ASL RMB
Arrhythmogenic Right Ventricular Dysplasia
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV).
- Trial name
- BRAVE (NCT03593317)
- Testing
- Spironolactone
- Where
- 13 sites in France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome
Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), Long QT Syndrome (LQTS)
- Trial name
- HiRO (NCT04189822)
- Where
- Canada
- Volunteers
- 10,000 people
- Sponsor
- University of British Columbia
Arrhythmogenic Cardiomyopathy, PKP2-ACM
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
- Conditions
- Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
- Trial name
- SNAPSHOT- PKP2 (NCT06976606)
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Lexeo Therapeutics
Arrhythmogenic Right Ventricular Cardiomyopathy
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
- Trial name
- RIDGE-1 (NCT06228924)
- Testing
- TN-401
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Tenaya Therapeutics
Arrhythmias, Cardiac, Atrial Fibrillation
Clinical Cohort Study - TRUST
The "Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg" (TRUST) study is an investor-initiated, single-center, prospective clinical…
- Conditions
- Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Ventricular Tachycardia
- Trial name
- TRUST (NCT05521451)
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf